Literature DB >> 12906374

Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome.

M Minetto1, A Dovio, M Ventura, S Cappia, F Daffara, M Terzolo, A Angeli.   

Abstract

Pheochromocytomas are tumors able to produce catecholamines and a variety of biologically active neuropeptides. We report the case of a 36-yr-old female patient with pheochromocytoma exhibiting headache, intermittent fever, thrombocytosis, and marked inflammatory signs. Nonsteroidal anti-inflammatory drugs were ineffective in lowering the body temperature, while a corticosteroid agent obtained excellent results. IL-6 was found elevated (20 pg/ml); it fell to 4.5 pg/ml 3 weeks after the adrenalectomy, in parallel to normalization of other laboratory data. The interleukin-6 (IL-6) over-production can either be ascribed directly to the tumor (as confirmed by immunohistochemistry) or indirectly accounted for by tumoral production, as a consequence of the high levels of circulating norepinephrine. To our knowledge, our paper represents the 6th case report of IL-6 secreting pheochromocytoma associated with clinical markers of inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906374     DOI: 10.1007/BF03345202

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  46 in total

1.  Secretion of vasopressin from a human pheochromocytoma.

Authors:  G Boccara; C Mann; G Guillon
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

2.  Interleukin-6 in the fever and multiorgan crisis of pheochromocytoma.

Authors:  A Salahuddin; T Rohr-Kirchgraber; R Shekar; B West; J Loewenstein
Journal:  Scand J Infect Dis       Date:  1997

3.  Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs.

Authors:  C Shimizu; M Kubo; K Takano; A Takano; H Kijima; H Saji; I Katsuyama; H Sasano; T Koike
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

4.  Circadian interleukin-6 secretion and quantity and depth of sleep.

Authors:  A N Vgontzas; D A Papanicolaou; E O Bixler; A Lotsikas; K Zachman; A Kales; P Prolo; M L Wong; J Licinio; P W Gold; R C Hermida; G Mastorakos; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

5.  Tumour angiogenesis and Ki-67 expression in phaeochromocytoma.

Authors:  H Ohji; I Sasagawa; O Iciyanagi; Y Suzuki; T Nakada
Journal:  BJU Int       Date:  2001-03       Impact factor: 5.588

Review 6.  The soluble IL-6 receptors: serum levels and biological function.

Authors:  F A Montero-Julian
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001-06       Impact factor: 1.770

7.  KAT45 human pheochromocytoma cell line. A new model for the in vitro study of neuro-immuno-hormonal interactions.

Authors:  M Venihaki; A Gravanis; A N Margioris
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

8.  Interleukin-6-producing pheochromocytoma.

Authors:  K Suzuki; A Miyashita; Y Inoue; S Iki; H Enomoto; Y Takahashi; T Takemura
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

9.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

10.  The value of plasma markers for the clinical behaviour of phaeochromocytomas.

Authors:  E van der Harst; W W de Herder; R R de Krijger; H A Bruining; H J Bonjer; S W J Lamberts; A H van den Meiracker; T H Stijnen; F Boomsma
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

View more
  10 in total

1.  Pheochromocytoma: a permanent challenge for the clinical endocrinologist.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

2.  Pheochromocytoma multisystem crisis successfully treated by emergency surgery: report of a case.

Authors:  Naotaka Uchida; Kiyosuke Ishiguro; Takako Suda; Motonobu Nishimura
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

3.  Ectopic hormone-secreting pheochromocytoma: a francophone observational study.

Authors:  James Kirkby-Bott; Laurent Brunaud; Muriel Mathonet; Etienne Hamoir; Jean-Louis Kraimps; Christophe Trésallet; Laurence Amar; Alexandre Rault; Jean-Francois Henry; Bruno Carnaille
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

4.  Intrahepatic cholestasis as a paraneoplastic syndrome associated with pheochromocytoma.

Authors:  C H Chung; C H Wang; C Y Tzen; C P Liu
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 5.  Functioning adrenocortical oncocytoma: the first documented case producing interleukin-6 and review of the literature.

Authors:  T Akatsu; K Kameyama; K Araki; T Ashizawa; G Wakabayashi; M Kitajima
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

6.  Interleukin-6-producing pheochromocytoma presenting with fever of unknown origin.

Authors:  Sema Yarman; Ozlem Soyluk; Esma Altunoglu; Refik Tanakol
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Concomitant multiple myeloma and probable phaeochromocytoma in a cat.

Authors:  Mario Cervone
Journal:  JFMS Open Rep       Date:  2017-07-21

8.  Paraganglioma presenting as hypertension during pregnancy, proteinuria, thrombocytosis, and diabetes mellitus: a case report.

Authors:  Ramjan Sanas Mohamed; Charles Naveenan Antonypillai; Harishanthi Mahendran
Journal:  J Med Case Rep       Date:  2021-07-09

Review 9.  Contribution of α - and β -Adrenergic Mechanisms to the Development of Pulmonary Edema.

Authors:  Beate Rassler
Journal:  Scientifica (Cairo)       Date:  2012-08-07

10.  Interleukin-6 producing pheochromocytoma/paraganglioma: case series from a tertiary referral centre for pheochromocytomas and paragangliomas.

Authors:  A C Meijs; M A Schroijen; M Snel; E P M Corssmit
Journal:  J Endocrinol Invest       Date:  2021-03-14       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.